RT Journal Article
SR Electronic
T1 Resistance to alkylating anticancer drugs: Role of the Nrf2-antioxidant system
JF Cancer Research
JO Cancer Res
FD American Association for Cancer Research
SP 705
OP 705
VO 68
IS 9 Supplement
A1 Manandhar, Sarala
A1 Cho, Jeong-Min
A1 Park, Hyun-Min
A1 Kwak, Mi-Kyoung
YR 2008
UL http://cancerres.aacrjournals.org/content/68/9_Supplement/705.abstract
AB AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA 705 The treatment of alkylating cytotoxic drug cisplatin is often limited by high incidence rate of resistance. In the present study, the potential involvement of the transcription factor Nrf2 in determination of cisplatin cytotoxicity has been investigated. Nrf2-deficient murine embryonic fibroblasts showed increased cell death, cytotoxicity, and apoptosis in response to cisplatin treatment compared to wild-type cells. Cisplatin-resistant human ovarian cancer SK-OV cells, which are retaining 25-fold higher levels of GSH than murine fibroblasts, could be sensitized by inhibition of Nrf2. Transfection with Nrf2 siRNA into SK-OV cells resulted in severe degree of GSH depletion and exacerbated cytotoxicity following cisplatin treatment compared to scrambled RNA control. In conclusion, we propose that the Nrf2 pathway, which plays a protective role in normal cells, can be a potential target to control cancer cell resistance to oxidants, cytotoxic chemicals, and radiation.